Relentlessly focused on advancing the treatment of inflammation and cancer
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to treat inflammatory diseases and conquer cancer in our lifetime. Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammation and cancer, and improve and empower countless lives. Join us in our quest.
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 13, 2023
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 03, 2023
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
You are leaving RAPT.com to go to the eczema clinical trial study site.